099190.KQ
i-SENS, Inc.
KOE · Healthcare · Medical - Specialties · KR
KRW 16,470.00
−2.72%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 326.2B | 315.7B | 291.1B | 265.1B | 264.8B |
| Cost of Revenue | 201.4B | 196.9B | 177.6B | 159.1B | 159.4B |
| Gross Profit | 124.8B | 118.6B | 113.5B | 106.1B | 105.5B |
| Operating Expenses | |||||
| R&D Expense | 27.8B | 32.6B | 30.3B | 27.0B | 27.0B |
| SG&A Expense | 27.0B | 35.3B | 32.3B | 26.9B | 21.6B |
| General & Admin Expense | 6.5B | 8.6B | 8.9B | 7.2B | 7.1B |
| Selling & Marketing Expense | 20.5B | 26.7B | 23.4B | 19.7B | 14.4B |
| Other Expenses | 67.8B | 43.3B | 48.3B | 41.2B | 37.1B |
| Total Operating Expenses | 113.1B | 111.2B | 110.9B | 95.1B | 85.7B |
| Cost and Expenses | 315.6B | 307.4B | 288.5B | 254.2B | 245.0B |
| Operating Income (EBIT) | 10.0B | 7.9B | 2.7B | 10.9B | 19.8B |
| Non-Operating | |||||
| Interest Income | 2.3B | 2.7B | 2.0B | 2.0B | 2.1B |
| Interest Expense | 6.5B | 7.2B | 6.9B | 3.0B | 1.9B |
| Net Interest Income | (4.2B) | (4.5B) | (4.9B) | (1.0B) | 248.6M |
| Other Non-Op Income/Expense | (15.9B) | (18.6B) | (1.0B) | (4.8B) | (653.7M) |
| Non-Operating Income (excl Interest) | 12.0B | — | (5.9B) | 1.8B | (1.2B) |
| EBT (Pre-Tax Income) | (5.9B) | (10.7B) | 1.7B | 6.1B | 19.2B |
| Income Tax Expense | (1.8B) | (4.0B) | 3.6B | 2.7B | 3.2B |
| Bottom Line | |||||
| Net Income | (2.7B) | (5.1B) | (1.8B) | 3.7B | 16.1B |
| Earnings from Cont. Ops | (4.1B) | (6.7B) | (2.0B) | 3.4B | 15.9B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (3.2B) | (5.1B) | (1.8B) | 3.7B | 16.1B |
| Per Share | |||||
| Basic EPS | (₩112) | (₩187) | (₩65) | ₩135 | ₩588 |
| Diluted EPS | (₩112) | (₩187) | (₩65) | ₩134 | ₩588 |
| Revenue Per Share | ₩12,247 | ₩11,434 | ₩10,548 | ₩9,642 | ₩9,653 |
| Shares | |||||
| Basic Shares Outstanding | 26.6M | 27.6M | 27.6M | 27.5M | 27.4M |
| Diluted Shares Outstanding | 26.6M | 27.6M | 27.6M | 27.7M | 27.5M |
| Profitability Metrics | |||||
| EBITDA | (3.6B) | 24.6B | 24.4B | 22.7B | 33.1B |
| D&A | 17.8B | 17.2B | 15.9B | 13.6B | 12.1B |
| EBIT | (21.4B) | 7.4B | 8.5B | 9.1B | 21.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026